Comment Resolutions: Difference between revisions
Jump to navigation
Jump to search
mNo edit summary |
No edit summary |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 69: | Line 69: | ||
| [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | | [[Media:QIBA MSK BC Public Comment Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
| [[Media:QIBA DCE- | | [[Media:QIBA DCE-Profile - v2.0 - Consensus Document.pdf|MR DCE-MRI Quantification (DCEMRI-Q) 2023-12-06]] | ||
| | | Consensus | ||
| | | 2023.12-06 | ||
| | | [[Media:QIBA DCE-MRI Public Comment Resolutions.pdf| Public Comment Resolutions]] | ||
|- | |- | ||
| [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | | [[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf| MR Elastography of the Liver 2022-02-14]] | ||
| Line 85: | Line 85: | ||
|- | |- | ||
| [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | | [[Media:QIBA PDFF Profile Stage2 FINAL.pdf| MR MRI-Based Proton Density Fat Fraction (PDFF) of the Liver 2023-12-04]] | ||
| | |Consensus | ||
|2023.09.08 | |2023.09.08 | ||
|Public Comment Resolutions 2023-11-14 | | [[Media:QIBA PDFF Public Comment Resolutions.pdf| Public Comment Resolutions 2023-11-14]] | ||
|- | |- | ||
| colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | | colspan="4" align="center" style="background:#dddddd" | '''PET/NM Profiles''' | ||
| Line 128: | Line 128: | ||
| [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | | [[Media:QIBA US SWS Comments 2023-02-20-v2.xlsx| Clinically Feasible Comment Resolutions 2023-02-20]] | ||
|- | |- | ||
| [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07]] | | [[Media:QIBA US SWS Profile 2023-02-07.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, marked-up version]] | ||
| Clinically Feasible | |||
| 2023.12.13 | |||
| [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | |||
|- | |||
| [[Media:SWS Profile Final Candidate February 07 2023 CLEAN.pdf|US Shear Wave Speed for Liver Fibrosis 2023-02-07, clean version]] | |||
| Clinically Feasible | | Clinically Feasible | ||
| 2023.12.13 | | 2023.12.13 | ||
| [[Media: | | [[Media:2023 12 13 SWS BC QIBA Technical Confirmation Resolutions.xlsx| Clinically Feasible Comment Resolutions 2023-12-13]] | ||
|- | |||
| [[Media:QIBA US VBF Profile 2023-12-13-tracked-changes.pdf|US Volume Blood Flow (VBF) Profile 2023-12-13 (tracked changes)]] | |||
| Consensus | |||
| 2023.12.13 | |||
| [[Media:2023 12 13 VBF BC QIBA Consensus Confirmation Resolutions.xlsx| Consensus Comment Resolutions 2023-12-13]] | |||
|- | |- | ||
|} | |} | ||
Latest revision as of 14:53, 21 December 2023
Comments received during Public Comment, Clinically Feasible (formerly Technical) Confirmation, or during a Profile ballot, are reviewed by the originating Biomarker Committee.
Per the QIBA Process, committees record how each collected comment was resolved and those resolutions are posted here.